LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Generalized pustular psoriasis or von Zumbusch psoriasis. Red, painful, tender skin blotches show up over a wide area of your body, and pus-filled blisters pop up soon after.

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe ...